GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » bioAffinity Technologies Inc (NAS:BIAF) » Definitions » Gross Margin %

bioAffinity Technologies (bioAffinity Technologies) Gross Margin % : 24.76% (As of Dec. 2023)


View and export this data going back to 2022. Start your Free Trial

What is bioAffinity Technologies Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. bioAffinity Technologies's Gross Profit for the three months ended in Dec. 2023 was $0.55 Mil. bioAffinity Technologies's Revenue for the three months ended in Dec. 2023 was $2.21 Mil. Therefore, bioAffinity Technologies's Gross Margin % for the quarter that ended in Dec. 2023 was 24.76%.


The historical rank and industry rank for bioAffinity Technologies's Gross Margin % or its related term are showing as below:

BIAF' s Gross Margin % Range Over the Past 10 Years
Min: 31.28   Med: 55.64   Max: 80
Current: 31.28


During the past 4 years, the highest Gross Margin % of bioAffinity Technologies was 80.00%. The lowest was 31.28%. And the median was 55.64%.

BIAF's Gross Margin % is ranked worse than
73.36% of 214 companies
in the Medical Diagnostics & Research industry
Industry Median: 46.155 vs BIAF: 31.28

bioAffinity Technologies had a gross margin of 24.76% for the quarter that ended in Dec. 2023 => Competition eroding margins

The 5-Year average Growth Rate of Gross Margin for bioAffinity Technologies was 0.00% per year.


bioAffinity Technologies Gross Margin % Historical Data

The historical data trend for bioAffinity Technologies's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

bioAffinity Technologies Gross Margin % Chart

bioAffinity Technologies Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Gross Margin %
- - 80.00 31.28

bioAffinity Technologies Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 95.00 75.17 24.76

Competitive Comparison of bioAffinity Technologies's Gross Margin %

For the Diagnostics & Research subindustry, bioAffinity Technologies's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


bioAffinity Technologies's Gross Margin % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, bioAffinity Technologies's Gross Margin % distribution charts can be found below:

* The bar in red indicates where bioAffinity Technologies's Gross Margin % falls into.



bioAffinity Technologies Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

bioAffinity Technologies's Gross Margin for the fiscal year that ended in Dec. 2023 is calculated as

Gross Margin % (A: Dec. 2023 )=Gross Profit (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=0.8 / 2.532
=(Revenue - Cost of Goods Sold) / Revenue
=(2.532 - 1.74) / 2.532
=31.28 %

bioAffinity Technologies's Gross Margin for the quarter that ended in Dec. 2023 is calculated as


Gross Margin % (Q: Dec. 2023 )=Gross Profit (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=0.5 / 2.213
=(Revenue - Cost of Goods Sold) / Revenue
=(2.213 - 1.665) / 2.213
=24.76 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


bioAffinity Technologies  (NAS:BIAF) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

bioAffinity Technologies had a gross margin of 24.76% for the quarter that ended in Dec. 2023 => Competition eroding margins


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


bioAffinity Technologies Gross Margin % Related Terms

Thank you for viewing the detailed overview of bioAffinity Technologies's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


bioAffinity Technologies (bioAffinity Technologies) Business Description

Traded in Other Exchanges
N/A
Address
22211 W Interstate 10, Suite 1206, San Antonio, TX, USA, 78257
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company is involved in developing technologies that, in the future, will be able to detect and monitor diseases of the lung and other cancers and treat many cancers.
Executives
Roby Joyce director 22211 W INTERSTATE 10, SUITE 1206, SAN ANTONIO TX 78257
Xavier Trinidad Reveles officer: Chief Operating Officer 22211 W INTERSTATE 10, SUITE 1206, SAN ANTONIO TX 78257
Michael Philip Dougherty officer: Chief Financial Officer 2934 SCATTERED OAKS ST, SAN ANTONIO TX 78232
James Michael Edwards officer: Chief Financial Officer 30907 KEENELAND DRIVE, FAIR OAKS RANCH TX 78015
Peter S Knight director 6702 STEIN CIRCLE, #642, P.O. BOX 4138, PARK CITY UT 84060
Steven Girgenti director, officer: Executive Chairman C/O HEALTHWORLD CORP, 100 AVENUE OF THE AMERICAS, NEW YORK NY 10013
Robert A. Anderson director 70 DOPPLER, IRVINE CA 92618
Gary D Rubin director, 10 percent owner 2080 NW BOCA RATON BLVD, STE 2, BOCA RATON FL 33431
Stuart Diamond director 498 SEVENTH AVE, NEW YORK NY 10018
Maria Zannes director, officer: President, CEO 19702 BELLA LOMA, #6005, SAN ANTONIO TX 78256
Harvey Sandler Revocable Trust 10 percent owner 21170 N. E. 22ND COURT, NORTH MIAMI BEACH FL 33180
Mohsin Y Meghji director C/O LOUGHLIN MEGHJI + COMPANY, NEW YORK NY 10016
Vivienne I Rebel officer: EVP, Chief Sci. & Med. Officer 8922 APACHE TRAIL, SAN ANTONIO TX 78255
Timothy P Zannes officer: Secretary, EVP, Gen. Counsel 1510 VISTA LARGA CT. NE, ALBUQUERQUE NM 87106
Nathan M Perlmutter 10 percent owner 28 PARRISH POND LANE, SOUTHAMPTON NY 11968